1.16
+0.01(+0.87%)
Currency In USD
| Previous Close | 1.15 |
| Open | 1.15 |
| Day High | 1.18 |
| Day Low | 1.09 |
| 52-Week High | 1.72 |
| 52-Week Low | 0.87 |
| Volume | 3.85M |
| Average Volume | 2.56M |
| Market Cap | 452.83M |
| PE | -8.92 |
| EPS | -0.13 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 1.22 |
| Change | 0.01 |
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 12:00 PM GMT
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard Bi
Standard BioTools Completes Sale of SomaLogic to Illumina
GlobeNewswire Inc.
Jan 30, 2026 2:09 PM GMT
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fu
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 millionBOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“St